Andrew Wei, MBBS, PhD, is an Adjunct Associate Professor at the Monash University, Melbourne, Australia, and Head of Leukemia Research at the Alfred Hospital, Melbourne, Australia. Prof. Wei completed his medical training in clinical and laboratory hematology at the University of Melbourne, Melbourne, Australia, in 2001. Prof. Wei is the recipient of a clinical scholarship from the Leukemia Foundation of Australia, as well as the Baikie medal in 2003.
Prof. Wei has been the Acute Myeloid Leukemia Disease Group Chairperson of the Australasian Leukemia and Lymphoma Group (ALLG) since 2009 and is also an executive member of the ALLG Scientific Advisory Committee.
Speaking on acute myeloid leukemia and novel therapeutic targets
Prof. Wei’s research interest primarily lies in developing novel therapeutic targets for the treatment of acute myeloid leukemia (AML) as well as using genomic techniques to identify targets associated with drug resistance. One of the key clinical trials he has been involved in include a Phase III trial assessing venetoclax plus low-dose cytarabine (LDAC) in patients with AML ineligible for chemotherapy.